Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ENZY's Cash to Debt is ranked higher than
72% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ENZY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ENZY' s Cash to Debt Range Over the Past 10 Years
Min: 0.46  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.92
ENZY's Equity to Asset is ranked higher than
87% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ENZY: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
ENZY' s Equity to Asset Range Over the Past 10 Years
Min: 0.67  Med: 0.90 Max: 0.93
Current: 0.92
0.67
0.93
Interest Coverage No Debt
ENZY's Interest Coverage is ranked lower than
55% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ENZY' s Interest Coverage Range Over the Past 10 Years
Min: 8.09  Med: 19.76 Max: 9999.99
Current: No Debt
8.09
9999.99
F-Score: 5
Z-Score: 12.11
M-Score: -2.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 12.73
ENZY's Operating margin (%) is ranked higher than
80% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. ENZY: 12.73 )
Ranked among companies with meaningful Operating margin (%) only.
ENZY' s Operating margin (%) Range Over the Past 10 Years
Min: -1.51  Med: 14.76 Max: 18.1
Current: 12.73
-1.51
18.1
Net-margin (%) 13.94
ENZY's Net-margin (%) is ranked higher than
83% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. ENZY: 13.94 )
Ranked among companies with meaningful Net-margin (%) only.
ENZY' s Net-margin (%) Range Over the Past 10 Years
Min: -3.75  Med: 14.64 Max: 17.54
Current: 13.94
-3.75
17.54
ROE (%) 5.10
ENZY's ROE (%) is ranked higher than
81% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. ENZY: 5.10 )
Ranked among companies with meaningful ROE (%) only.
ENZY' s ROE (%) Range Over the Past 10 Years
Min: 3.19  Med: 6.37 Max: 6.52
Current: 5.1
3.19
6.52
ROA (%) 4.71
ENZY's ROA (%) is ranked higher than
84% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ENZY: 4.71 )
Ranked among companies with meaningful ROA (%) only.
ENZY' s ROA (%) Range Over the Past 10 Years
Min: 5.71  Med: 9.90 Max: 12.16
Current: 4.71
5.71
12.16
ROC (Joel Greenblatt) (%) 10.43
ENZY's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. ENZY: 10.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENZY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 13.81  Med: 27.97 Max: 29.34
Current: 10.43
13.81
29.34
» ENZY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ENZY Guru Trades in Q4 2014

John Paulson 4,238,275 sh (-0.77%)
» More
Q1 2015

ENZY Guru Trades in Q1 2015

Jim Simons 54,200 sh (New)
John Paulson 4,238,275 sh (unchged)
» More
Q2 2015

ENZY Guru Trades in Q2 2015

Jim Simons 82,494 sh (+52.20%)
John Paulson 4,238,275 sh (unchged)
» More
Q3 2015

ENZY Guru Trades in Q3 2015

Julian Robertson 804,854 sh (New)
Jim Simons 146,000 sh (+76.98%)
John Paulson 4,238,275 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ENZY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Enzymotec Ltd

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Biotech company is up 25% for the year
Guru Julian Robertson (Trades, Portfolio) is a legendary billionaire investor and founder of Tiger Management, which netted an outstanding average return of 32% from 1980 to 2000. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.66
ENZY's P/E(ttm) is ranked lower than
54% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.70 vs. ENZY: 29.66 )
Ranked among companies with meaningful P/E(ttm) only.
ENZY' s P/E(ttm) Range Over the Past 10 Years
Min: 16.71  Med: 44.26 Max: 146.67
Current: 29.66
16.71
146.67
Forward P/E 21.69
ENZY's Forward P/E is ranked lower than
66% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.58 vs. ENZY: 21.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 29.66
ENZY's PE(NRI) is ranked higher than
50% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 31.00 vs. ENZY: 29.66 )
Ranked among companies with meaningful PE(NRI) only.
ENZY' s PE(NRI) Range Over the Past 10 Years
Min: 8.88  Med: 25.43 Max: 55.87
Current: 29.66
8.88
55.87
P/B 1.53
ENZY's P/B is ranked higher than
72% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. ENZY: 1.53 )
Ranked among companies with meaningful P/B only.
ENZY' s P/B Range Over the Past 10 Years
Min: 0.99  Med: 1.65 Max: 11
Current: 1.53
0.99
11
P/S 4.29
ENZY's P/S is ranked higher than
71% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. ENZY: 4.29 )
Ranked among companies with meaningful P/S only.
ENZY' s P/S Range Over the Past 10 Years
Min: 1.16  Med: 3.45 Max: 5.82
Current: 4.29
1.16
5.82
PFCF 26.16
ENZY's PFCF is ranked higher than
53% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 28.77 vs. ENZY: 26.16 )
Ranked among companies with meaningful PFCF only.
ENZY' s PFCF Range Over the Past 10 Years
Min: 21.53  Med: 45.78 Max: 519
Current: 26.16
21.53
519
POCF 18.92
ENZY's POCF is ranked higher than
59% of the 380 Companies
in the Global Biotechnology industry.

( Industry Median: 27.35 vs. ENZY: 18.92 )
Ranked among companies with meaningful POCF only.
ENZY' s POCF Range Over the Past 10 Years
Min: 9.88  Med: 25.36 Max: 1030
Current: 18.92
9.88
1030
EV-to-EBIT 25.19
ENZY's EV-to-EBIT is ranked lower than
62% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 19.35 vs. ENZY: 25.19 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.1  Med: 26.70 Max: 61.8
Current: 25.19
7.1
61.8
EV-to-EBITDA 18.52
ENZY's EV-to-EBITDA is ranked lower than
59% of the 457 Companies
in the Global Biotechnology industry.

( Industry Median: 16.36 vs. ENZY: 18.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 19.85 Max: 54.6
Current: 18.52
6.2
54.6
Current Ratio 8.34
ENZY's Current Ratio is ranked higher than
70% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. ENZY: 8.34 )
Ranked among companies with meaningful Current Ratio only.
ENZY' s Current Ratio Range Over the Past 10 Years
Min: 2.31  Med: 7.02 Max: 8.76
Current: 8.34
2.31
8.76
Quick Ratio 6.15
ENZY's Quick Ratio is ranked higher than
61% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ENZY: 6.15 )
Ranked among companies with meaningful Quick Ratio only.
ENZY' s Quick Ratio Range Over the Past 10 Years
Min: 1.5  Med: 5.52 Max: 7.31
Current: 6.15
1.5
7.31
Days Inventory 419.05
ENZY's Days Inventory is ranked lower than
94% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. ENZY: 419.05 )
Ranked among companies with meaningful Days Inventory only.
ENZY' s Days Inventory Range Over the Past 10 Years
Min: 121.07  Med: 143.84 Max: 333.94
Current: 419.05
121.07
333.94
Days Sales Outstanding 122.82
ENZY's Days Sales Outstanding is ranked lower than
80% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. ENZY: 122.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 108  Med: 117.86 Max: 128.19
Current: 122.82
108
128.19
Days Payable 189.00
ENZY's Days Payable is ranked higher than
82% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. ENZY: 189.00 )
Ranked among companies with meaningful Days Payable only.
ENZY' s Days Payable Range Over the Past 10 Years
Min: 107.56  Med: 135.03 Max: 175.92
Current: 189
107.56
175.92

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.52
ENZY's Price/Net Cash is ranked lower than
54% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: 5.77 vs. ENZY: 6.52 )
Ranked among companies with meaningful Price/Net Cash only.
ENZY' s Price/Net Cash Range Over the Past 10 Years
Min: 5.38  Med: 7.28 Max: 10.39
Current: 6.52
5.38
10.39
Price/Net Current Asset Value 3.06
ENZY's Price/Net Current Asset Value is ranked higher than
67% of the 849 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ENZY: 3.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ENZY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.55  Med: 2.97 Max: 14.91
Current: 3.06
2.55
14.91
Price/Tangible Book 1.62
ENZY's Price/Tangible Book is ranked higher than
82% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ENZY: 1.62 )
Ranked among companies with meaningful Price/Tangible Book only.
ENZY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.18  Med: 1.57 Max: 6.81
Current: 1.62
1.18
6.81
Price/Median PS Value 1.30
ENZY's Price/Median PS Value is ranked lower than
71% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. ENZY: 1.30 )
Ranked among companies with meaningful Price/Median PS Value only.
ENZY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.33  Med: 0.83 Max: 1.26
Current: 1.3
0.33
1.26
Price/Graham Number 1.50
ENZY's Price/Graham Number is ranked higher than
62% of the 407 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. ENZY: 1.50 )
Ranked among companies with meaningful Price/Graham Number only.
ENZY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.16  Med: 1.45 Max: 1.84
Current: 1.5
1.16
1.84
Earnings Yield (Greenblatt) (%) 4.01
ENZY's Earnings Yield (Greenblatt) (%) is ranked higher than
83% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. ENZY: 4.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENZY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 3.75 Max: 14
Current: 4.01
1.6
14

More Statistics

Revenue(Mil) $48
EPS $ 0.30
Short Percentage of Float0.48%
52-Week Range $5.38 - 10.83
Shares Outstanding(Mil)22.48

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 50 58
EPS($) 0.33 0.43
EPS without NRI($) 0.33 0.43

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:EZ4.Germany,
» More Articles for ENZY

Headlines

Articles On GuruFocus.com
Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Dec 07 2015 
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
Enzymotec to Report Fourth Quarter and Full Year 2015 Financial Results Feb 03 2016
Enzymotec Announces Positive Outcome in ICC Arbitration Award Feb 02 2016
2016-01-28 NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING IN ENZYMATICA AB (PUBL) Jan 28 2016
2016-01-28 Enzymatica signs acquisition agreement and prepares for international expansion with new... Jan 28 2016
Enzymotec Updates Automatic Extension of Its Joint Venture Agreement With AAK Until December 31,... Jan 04 2016
Enzymotec Updates Automatic Extension of Its Joint Venture Agreement With AAK Until December 31,... Jan 04 2016
Enzymotec Ltd. Earnings Analysis: Q3, 2015 By the Numbers Dec 23 2015
Enzymotec Granted Mexican Patent for INFAT® Uses Related to Promoting Intestinal Health Dec 21 2015
Hedge Fund Sentiment Is Stagnant On Enzymotec Ltd (ENZY) Dec 09 2015
Appaloosa Management Sends Letter To TerraForm Power & Three Other Notable Hedge Fund Moves Dec 08 2015
ENZYMOTEC LTD. Financials Dec 08 2015
Tiger Management Founder Julian Robertson Ups Stake in Enzymotec Dec 07 2015
Enzymotec's InCog(TM), an Innovative Lipid Composition for Cognitive Functioning, Approved as Novel... Dec 01 2015
Why Enzymotec (ENZY) Could Be Positioned for a Surge? Nov 23 2015
2015-11-12 Enzymatica signs distribution agreement with Esteve in Spain Nov 12 2015
Enzymotec Ltd. Reports Third Quarter 2015 Results Nov 11 2015
Enzymotec beats 3Q profit forecasts Nov 11 2015
Enzymotec beats 3Q profit forecasts Nov 11 2015
Enzymotec to Host a VAYA Pharma Analyst and Investor Day in New York City on November 19, 2015 Nov 10 2015
2015-11-10 Enzymatica signs distribution agreement with Tamro for the Finnish market Nov 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK